

## SCRI Trials and Trial Regimen Updates

The following updates were completed between April 18, 2025, through May 16, 2025. Sarah Cannon Research Institute now manages all SCRI/USOR trials and trial regimens. For questions about these trials and regimens, please contact [SCRiKMEMRedits@McKesson.com](mailto:SCRiKMEMRedits@McKesson.com).

### New Builds Completed

Study Number	Notes for New Build
24119	USOR 24119 LUN 568 Phase 2 Dose Optimization Part 1 AMG 193 Q28D
24114	USOR 24114 GU 247 Phase 3 Control Arm Abiraterone Acetate + Prednisone Q30D USOR 24114 GU 247 Phase 3 Control Arm Cabazitaxel + Prednisone Q21D USOR 24114 GU 247 Phase 3 Control Arm Enzalutamide Q30D USOR 24114 GU 247 Phase 3 Experimental Arm Xaluritamig Q28D
24208	USOR 24208 BRE 449 Phase 2 Part 2 Arm A Pembrolizumab + HER3-DXd fb Pembrolizumab + Paclitaxel + Carboplatin Q21D USOR 24208 BRE 449 Phase 2 Part 2 Arm B Pembrolizumab + Paclitaxel + Carboplatin fb Pembrolizumab + HER3-DXd Q21D USOR 24208 BRE 449 Phase 2 Part 2 Arm C Pembrolizumab + Paclitaxel + Carboplatin fb Pembrolizumab + Doxorubicin or Epirubicin + Cyclophosphamide Q21D USOR 24208 BRE 449 Phase 2 Pembrolizumab +/- Capecitabine (Cycle 9+) Q42D USOR 24208 BRE 449 Phase 2 Pembrolizumab +/- Doxorubicin or Epirubicin + Cyclophosphamide (Q2W) Q42D (Cycle 9+) USOR 24208 BRE 449 Phase 2 Pembrolizumab +/- Doxorubicin or Epirubicin + Cyclophosphamide (Q3W) Q42D (Cycle 9+) USOR 24208 BRE 449 Phase 2 Pembrolizumab +/- Olaparib (Cycle 9+) Q42D USOR 24208 BRE 449 Phase 2 Part 1 Safety Lead-in Pembrolizumab + HER3-DXd fb Pembrolizumab + Paclitaxel + Carboplatin Q21D

Study Number	Notes for New Build
24207	USOR 24207 GU 248 Phase 2 Arm 1 Livmoniplimab + Budigalimab Q21D USOR 24207 GU 248 Phase 2 Arm 2 Livmoniplimab + Budigalimab Q21D USOR 24207 GU 248 Phase 2 Arm 3 Docetaxel Q21D USOR 24207 GU 248 Phase 2 Arm 3 Gemcitabine D1,8 Q21D USOR 24207 GU 248 Phase 2 Arm 3 Paclitaxel Q21D
24043	USOR 24043 GU 245 Phase 2 PET Imaging Agents AAA517 or Piflufolastat (18F) USOR 24043 GU 245 Phase 2 Arm B Lutetium (177Lu) vipivotide tetraxetan (AAA617) + ARPI Q42D USOR 24043 GU 245 Phase 2 Arm A Lutetium (177Lu) vipivotide tetraxetan (AAA617) Q42D
24126	USOR 24126 RM 858 Phase 2 BDTX-1535 Q21D
24153	USOR 24153 GI 382 Phase 3 Double-Blind Quemliclustsat or Placebo + Nab-Paclitaxel + Gemcitabine Q28D
24189	USOR 24189 LUN 579 Phase 2b Cohort 2 Amivantamab SC + Carboplatin + Pemetrexed Q21D USOR 24189 LUN 579 Phase 2b Cohort 1 Amivantamab SC + Lazertinib Q28D
24157	USOR 24157 MEL 75 Phase 3 Crossover (Arm B) NMA-LD + Lifileucel (off-site documentation) Q10D USOR 24157 MEL 75 Phase 3 Arm B Pembrolizumab (Initial) D5,26 USOR 24157 MEL 75 Phase 3 Arm A Pembrolizumab + NMA-LD + Lifileucel (off-site documentation) Q37D USOR 24157 MEL 75 Phase 3 All Arms Pembrolizumab Maintenance Q42D
24215	USOR 24215 LUN 578 Phase 2 Telisotuzumab Vedotin Q14D
23254	USOR 23254 MM 186 Phase 3 Arm B Pomalidomide + Bortezomib + Dexamethasone (PVd) Q21D USOR 23254 MM 186 Phase 3 Arm B Elotuzumab + Pomalidomide + Dexamethasone (EPd) Q28D USOR 23254 MM 186 Phase 3 Arm B Carfilzomib + Dexamethasone (Kd) Q28D USOR 23254 MM 186 Phase 3 Arm A Elranatamab Q28D

Study Number	Notes for New Build
24098	USOR 24098 GI 386 Phase 3 Arm B Cetuximab D1,8,15,22 + FOLFIRI Q28D USOR 24098 GI 386 Phase 3 Arm B Cetuximab D1,15 + FOLFIRI Q28D USOR 24098 GI 386 Phase 3 Arm B Bevacizumab + FOLFIRI Q28D USOR 24098 GI 386 Phase 3 Arm A Amivantamab + FOLFIRI Q28D
24239	USOR 24239 CLL 63 Phase 2 Arm B Zanubrutinib Q28D USOR 24239 CLL 63 Phase 2 Arm A Zanubrutinib fb Zanubrutinib + Sonrotoclax Q28D
24025	USOR 24025 MULTI 91 Phase 1b/2 Safety Run-In Ifinatumab Deruxtecan (I-DXd) Q21D (HCC) USOR 24025 MULTI 91 Phase 1b/2 Ifinatumab Deruxtecan (I-DXd) Q21D
22118	USOR 22118 LUN 552 Phase 3 Sotorasib + Pemetrexed + Carboplatin Q21D USOR 22118 LUN 552 Phase 3 Pembrolizumab + Pemetrexed + Carboplatin Q21D

## Updated Reference Information

Study Number	Updated Reference Information	Updated Regimen Instructions	Other Changes
23340	N/A	N/A	Added stability & drug instruction
22181	Master Amendment 5: 14 Nov 2024	N/A	Updated drug instruction
22252	Master Amendment 3: 25 Jun 2024	N/A	N/A
23283	N/A	N/A	Updated cycling
21320	Amendment 9 Version 10:	N/A	Added phase 2b arms
23335	Amendment 1.0: 23 Feb 2025	N/A	Set IP dose

Study Number	Updated Reference Information	Updated Regimen Instructions	Other Changes
23031	Amendment 5: 09 Apr 2025.	N/A	Updated weight calculation instructions
24077	N/A	N/A	Updated flush requirements
22201	N/A	N/A	Updated premedications
23172	N/A	N/A	Updated drug procurement and arms
22101	Amendment e: 31 Jan 2025.	N/A	Updated cycling
24010	Amendment v3: 12 Mar 2025	N/A	N/A
22037	Amendment v10 18 Nov 2025	Added premed instructions	Updated drug name, added premeds
24050	Amendment 4.0 28 Mar 2024	N/A	Updated IP arm to off-site documentation
23180	Amendment v2 17 Jan 2025	Updated observation comments	N/A
23269	Amendment v5.0 26 Nov 2024	Premedication clarification	Unchecked all premeds for SOC drugs
20186	Amendment v7 19 Feb 2025	N/A	Added Entrectinib drug admin instruction
23087	Amendment 3 21 Feb 2025	Updated observation wording	Added new form SQ to SOC drugs, added weight and stability instruction